摘要
目的:探讨尿激酶型纤溶酶原激活剂(uPA)、纤溶酶原激活物抑制剂(PAI-1)的表达和血管形成与浸润性乳腺癌侵袭性的关系。方法:应用免疫组化SP法检测80例浸润性乳腺癌、20例良性乳腺肿瘤组织中uPA、PAI-1的表达情况并进行微血管计数。结果:uPA和PAI-1在浸润性乳腺癌组的阳性表达显著高于良性肿瘤组,且其高表达率与乳腺癌的临床病理参数密切相关(P<0.05);微血管计数在乳腺癌组和良性肿瘤组分别为30.87±7.64、20.28±8.72,两组比较有显著性差异(P<0.01)。uPA与PAI-1在浸润性乳腺癌中的表达呈正相关(P<0.05)。结论:uPA、PAI-1的高表达与浸润性乳腺癌的浸润、转移相关,uPA、PAI-1的高表达和MVD计数可作为评价浸润性乳腺癌侵袭性、评估预后和确定治疗方案的生物学指标。
Objective:To detect the expression of uPA(urokinase plasminogen activator)、PAI-1(plasminogen activator inhibitor type 1) and angiogenesis in breast cancer and their relationship with the invasiveness of breast cancer.Methods:Eighty surgically resected breast cancer samples and twenty breast benign tumor samples were selected.S-P immunostaining technique was used to detect the expression of uPA、PAI-1and MVD in all of the tissues.Results:The positive expression rates of uPA、PAI-1 in breast cancer was significantly higher than that in the breast benign tumors,and their high expression rates were related with the clinical pathology parameters of the breast cancer(P0.05).MVD were respectively 30.87±7.64,20.28±8.72 in breast cancer and breast benign tumor group.There was significantly difference between the two groups(P0.01).There were positive correlations between the level of uPA and PAI-1 in breast cancer(P0.05).Conclusion:The expression of uPA and PAI-1 correlated with the invasiveness and metastasis of breast cancer,and they could be used as biological indicators that evaluate the invasiveness and metastasis,estimate prognosis and determine treatment of primary invasive breast cancer.
出处
《现代生物医学进展》
CAS
2011年第12期2307-2309,共3页
Progress in Modern Biomedicine